Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

off-the-shelf

Adapting cell therapies to solid tumors 2:57
Adapting cell therapies to solid tumors
Nina Bauer • 26 Jan 2022
The advantages and applications of CRISPR-Cas 9 1:47
The advantages and applications of CRISPR-Cas 9
Nina Bauer • 27 Jan 2022
Advantages of allogeneic NK cell therapy 2:26
Advantages of allogeneic NK cell therapy
Kanya Rajangam • 13 Oct 2021
Developments in NK cell therapy 2:48
Developments in NK cell therapy
Kanya Rajangam • 13 Oct 2021
Treating hematologic malignancies with immunotherapy 0:59
Treating hematologic malignancies with immunotherapy
Kanya Rajangam • 13 Oct 2021
Advances in cell-based therapies for MS 4:55
Advances in cell-based therapies for MS
Jakob Dupont • 17 Jun 2021
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Universal “off-the-shelf” CAR T-cells from iPSCs 4:58
Universal “off-the-shelf” CAR T-cells from iPSCs
Alexandros Nianias • 6 Feb 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy